Document and entity information

	Mar 2025	Dec 2024
Company information		
Company information		
FASF member mark		true
Document name		第３四半期決算短信〔日本基準〕（連結）
Filing date		2025-01-31
Company name		JCR Pharmaceuticals Co.,Ltd.
Securities code		4552
URL		https://www.jcrpharm.co.jp/
Representative		
Title		代表取締役会長兼社長
Name		芦田 信
Inquiries		
Title		上席執行役員経営戦略本部長
Name		伊藤 洋
Tel		0797(32)1995
Supplemental material of results		true
Way of getting		-
Convening briefing of results		true
Target for briefing of results		（機関投資家・アナリスト向け）
Note to fraction processing method		（百万円未満切捨て）
Stock exchange listings		
Tokyo		true
Tokyo Prime		true
Tokyo Standard		-
Tokyo Growth		-
Tokyo PRO Market		-
Tokyo Others		-
Nagoya		-
Nagoya Premire		-
Nagoya Main		-
Nagoya Next		-
Nagoya Others		-
Sapporo		-
Sapporo		-
Sapporo Ambitious		-
Sapporo Others		-
Fukuoka		-
Fukuoka		-
Fukuoka Q-Board		-
Fukuoka Others		-
Phoenix		-
Japan Securities Dealers Association		-
Business category		
General Business	true	
Specific Business	-	
Fiscal Year End	2025-03-31	
Quarterly period		3

Business Results-Quarterly operating results

(in millions of yens)

	Dec 2024	Dec 2023
Quarterly operating results		
Quarterly operating results		
Consolidated operating results		
Consolidated income statements information		
Net sales		
Net sales	25,880	33,718
% change	-23.2	26.3
Operating profit		
Operating profit	-754	7,809
% change	-	57.7
Ordinary profit		
Ordinary profit	-1,380	7,388
% change	-	39.6
Profit attributable to owners of parent		
Profit attributable to owners of parent	-576	5,160
% change	-	44.6
Note to consolidated income statements information		
Comprehensive income		
Comprehensive income	1,497	5,949
Change in comprehensive income	-74.8	57.6
Other consolidated operating results		
Basic earnings per share (Yen)	-4.63	41.35
Diluted earnings per share (Yen)	-	41.16
Note to consolidated operating results		
Note to operating results	（注）2025年３月期第３四半期の「潜在株式調整後１株当たり四半期純利益」については、潜在株式は存在するものの１株当たり四半期純損失であるため記載しておりません。	

Business Results-Quarterly financial positions

(in millions of yens)

	Dec 2024	Mar 2024
Quarterly financial positions		
Quarterly financial positions		
Consolidated financial positions		
Total assets	105,517	102,226
Net assets	52,972	56,475
Capital adequacy ratio (%)	49.8	54.2
Note to consolidated financial positions		
Owner's equity	52,500	55,365
Note to financial positions	-	

Business Results-Note to quarterly business results

	Dec 2024
Quarterly note to business results	
Quarterly note to business results	
Note to consolidated financial results	
Note to consolidated financial results	-

Quarterly Dividends

(in millions of yens)

	Mar 2025	Dec 2024	Mar 2024

Quarterly dividends			
Quarterly dividends			
Dividends			
Dividend per share (Yen)			
Dividend per share (Yen)			
First quarter			
Result	-		-
Second quarter			
Result		10.00	10.00
Third quarter			
Result	-		-
Year end			
Result			10.00
Forecast		10.00	
Upper	-		
Lower	-		
Annual			
Result			20.00
Forecast		20.00	
Upper	-		
Lower	-		
Correction of dividend forecast from the most recent dividend forecast			
Correction of dividend forecast from the most recent dividend forecast			
Annual	-		
Note to dividends			
Note to dividends			
Annual		-	

Quarterly Forecasts

(in millions of yens)

	Mar 2025
Quarterly forecasts	
Quarterly forecasts	
Title for forecasts	３．2025年３月期の連結業績予想（2024年４月１日～2025年３月31日）
Preamble to consolidated forecasts	
Preamble to forecasts	-
Main table of consolidated forecasts	
Net sales	
Net sales	
Forecast	39,000
Upper	-
Lower	-
% change	
Forecast	-9.0
Upper	-
Lower	-
Operating profit	
Operating profit	
Forecast	1,400
Upper	-
Lower	-
% change	
Forecast	-81.4
Upper	-
Lower	-
Ordinary profit	
Ordinary profit	
Forecast	750
Upper	-

Lower	-
% change	
Forecast	-89.7
Upper	-
Lower	-
Profit attributable to owners of parent	
Profit attributable to owners of parent	
Forecast	2,200
Upper	-
Lower	-
% change	
Forecast	-60.1
Upper	-
Lower	-
Basic earnings per share (Yen)	
Basic earnings per share (Yen)	
Forecast	17.77
Upper	-
Lower	-
Note to consolidated forecasts	
Note to forecasts	-
Correction of financial forecast from the most recent financial forecast	
Correction of financial forecast from the most recent financial forecast	
Forecast	true

Notes-Significant changes in the scope of consolidation during the period

(in millions of yens)

	Dec 2024
Significant changes in the scope of consolidation during the period	
Significant changes in the scope of consolidation during the period	
Others	
Significant changes in the scope of consolidation during the period	
Significant changes in the scope of consolidation during the period	true
Number of subsidiaries newly consolidated	-
Name of subsidiaries newly consolidated	-
Number of subsidiaries excluded from consolidation	1
Name of subsidiaries excluded from consolidation	Mycenax Biotech Inc.
Note to significant changes in the scope of consolidation during the period	
Note to significant changes in the scope of consolidation during the period	-

Notes, Quarterly-Applying of specific accounting of the consolidated quarterly financial statements

	Dec 2024
Applying of specific accounting of the consolidated quarterly financial statements	
Applying of specific accounting of the consolidated quarterly financial statements	
Others	
Applying of specific accounting of the consolidated quarterly financial statements	
Applying of specific accounting of the consolidated quarterly financial statements	-
Note to applying of specific accounting of the consolidated quarterly financial statements	
Note to applying of specific accounting of the consolidated quarterly financial statements	-

Notes, Quarterly-Changes in accounting policies and accounting estimates retrospective restatement

	Dec 2024
Changes in accounting policies, accounting estimates and retrospective restatement	
Changes in accounting policies, accounting estimates and retrospective restatement	
Others	
Changes in accounting policies, accounting estimates and retrospective restatement	
Changes in accounting policies based on revisions of accounting standard	true
Changes in accounting policies other than ones based on revisions of accounting standard	-
Changes in accounting estimates	-
Retrospective restatement	-
Note to changes in accounting policies, accounting estimates and retrospective restatement	
Note to changes in accounting policies, accounting estimates and retrospective restatement	（注）詳細は、添付資料９ページ「２．四半期連結財務諸表及び主な注記（３）四半期連結財務諸表に関する注記事項（会計方針の変更に関する注記）」をご覧ください。

Notes, Quarterly-Number of issued and outstanding shares common stock

	Dec 2024	Mar 2024	Dec 2023
Number of issued and outstanding shares (common stock)			
Number of issued and outstanding shares (common stock)			
Others			
Number of issued and outstanding shares (common stock)			
Number of issued and outstanding shares at the end of fiscal year (including treasury stock)	129,686,308	129,686,308	
Number of treasury stock at the end of fiscal year	7,861,502	4,881,914	
Average number of shares	124,422,312		124,791,093
Note to number of issued and outstanding shares (common stock)			
Note to number of issued and outstanding shares (common stock)	-		

This information is a summary of the earnings report. It does not contain all details included in the earnings report disclosed in Japanese.